The Law Offices of Frank R. Cruz Announces Investigation of EHang …
However, Wolfpack Research alleged that "Kunxiang signed sham sales contracts to benefit its investment stock price in EH," citing "extensive evidence including …
The Law Offices of Frank R. Cruz Announces Investigation of EHang Holdings Limited (EH) on Behalf of Investors to view your mail Finance Watchlists My Portfolio Screeners Premium Markets News Personal Finance Videos Industries Tech Contact Us MoreMore
U.S. markets close in 3 hours 1 minuteS&P 5003,917.87-14.72 (-0.37%)Dow 3031,519.83-2.92 (-0.01%)Nasdaq13,902.41-145.09 (-1.03%)Russell 20002,243.93-28.96 (-1.27%)Crude Oil60.43+0.38 (+0.63%)Gold1,778.10-20.90 (-1.16%)Silver27.42+0.09 (+0.33%)EUR/USD1.2050-0.0058 (-0.48%)10-Yr Bond1.2740-0.0250 (-1.92%)GBP/USD1.3857-0.0045 (-0.33%)USD/JPY105.7920-0.2880 (-0.27%)BTC-USD51,362.30+2,784.72 (+5.73%)CMC Crypto 2001,035.72+43.71 (+4.41%)FTSE 1006,710.90-37.96 (-0.56%)Nikkei 22530,292.19-175.56 (-0.58%)The Law Offices of Frank R. Cruz Announces Investigation of EHang Holdings Limited (EH) on Behalf of InvestorsRead full articleOops!Something went wrong.Please try again later.More content belowFebruary 17, 2021, 10:15 AM·2 min readOops!Something went wrong.Please try again later.More content below
announces an investigation of EHang Holdings Limited (“EHang” or the “Company”) (NASDAQ: ) on behalf of investors concerning the Company’s possible violations of federal securities laws.
If you are a shareholder who suffered a loss, click to participate.
On February 16, 2021, Wolfpack Research issued a research report entitled: “EHang: A Stock Promotion Destined to Crash and Burn,” concluding “that EH's relationship with its primary purported customer is a sham.” According to the report, “[g]overnment records and credit reports show that EH's major customer is Shanghai Kunxiang Intelligent Technology Co.” (“Kunxiang”). However, Wolfpack Research alleged that “Kunxiang signed sham sales contracts to benefit its investment stock price in EH,” citing “extensive evidence including behind-the-scenes photographs, recorded phone calls, and videos of on-site visits to EH's various facilities, as well as Kunxiang's offices.”
On this news, the Company’s stock price fell $77.79, or 62.69%, to close at $46.30 per share on February 16, 2021.
Follow us for updates on Twitter: .
If you purchased EHang securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 1999 Avenue of the Stars, Suite 1100, Los Angeles, California 90067 at 310-914-5007, by email to , or visit our website at . If you inquire by email please include your mailing address, telephone number, and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
View source version on businesswire.com:
The Law Offices of Frank R. Cruz, Los AngelesFrank R. Cruz, 310-914-5007
EHang Holdings Limited68.98+22.68+48.98%TRENDING 1. 2. 3. 4. 5.
Latest StoriesInvestor's Business Daily
Tilray reports fourth-quarter earnings after the close today, as its shares and other marijuana stocks gave up huge gains.
(Bloomberg) — Oil rose for a third session as an ongoing energy crisis in the U.S. pummeled domestic crude output.Futures edged up in New York after flipping between gains and losses earlier on Wednesday. The deep freeze causing historic power outages across the central U.S. has led oil output in the country to plunge by a third. However, a spate of refinery outages from the cold temperatures are curbing demand for crude.“There’s a push-pull there, as production’s knocked off, but the refiners are down too,” said John Kilduff, a partner at Again Capital LLC. “But it’ll be like a hurricane, in that it’ll pass.”Crude’s rally faded briefly during Wednesday’s session after Dow Jones reported that Saudi Arabia plans to boost oil output in the coming months, citing unnamed advisers to the kingdom. While Saudi Arabia’s unilateral supply cuts this year came as a surprise to the market when initially announced, many investors had expected the producer to raise output come April. Meanwhile, Saudi Arabia is urging fellow members of the OPEC+ alliance to remain cautious as they prepare to consider further supply increases.“We’re at a very delicate point here,” said Bob Yawger, head of the futures division at Mizuho Securities. OPEC+ has “to make sure the associated demand is there before increasing the barrels and not kill the golden goose here, which is what they’ll do if they add everything at once.”Temperatures in Texas are now low enough to freeze oil and gas liquids at the well head and in pipelines laid on the ground. Before the crisis, the U.S. was pumping about 11 million barrels a day, according to government data. Production in the Permian Basin alone — America’s biggest oil field — has plummeted by as much as 65%.A slew of crude pipelines were also shut earlier this week due to the freeze, including those that transport oil from the nation’s largest storage hub at Cushing, Oklahoma to the U.S. Gulf Coast, according to data-provider Genscape Inc. Multiple pipelines remained offline as of Tuesday.While WTI’s nearest timespread flipped back into contango this week amid refinery closures and infrastructure issues associated with the freeze in the U.S., the similar spread for Brent has moved into an even more bullish backwardation structure.In Russia, meanwhile, freezing temperatures are also contributing to production curtailments. The expected increase in the nation’s February oil output has so far not materialized, as some fields curb pipeline flows due to the abnormally cold weather.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.
15m agoYahoo Finance
Warren Buffett goes on the hunt for stocks in the fourth quarter, according to a new filing.
As part of COVID-19 relief, you can now keep your home loan on pause for up to 18 months.
Congressional leaders may shift into an even faster gear in a race against the calendar.
Microsoft Corporation (NASDAQ: MSFT) co-founder Bill Gates praised Tesla Inc’s (NASDAQ: TSLA) and its CEO Elon Musk's contributions on mitigating climate change in a New York Times Co (NYSE: NYT) podcast this week. What Happened: “Well, it’s important to say that what Elon did with Tesla is one of the greatest contributions to climate change anyone’s ever made,” the billionaire-philanthropist said on NYT opinion writer Kara Swisher’s twice-weekly podcast “Sway.” “Underestimating Elon is not a good idea,” Gates added. Why It Matters: The Microsoft co-founder's comments follow Musk's appearance on Joe Rogan's podcast where he expressed a belief that Gates had a short position on Tesla stock, Electrek reported. “I also heard that at one point he had a large short position. I don’t know if that’s true or not, but it seems weird,” said Musk. “People I know who know the situation pretty well, I asked them 'are you sure?' and they said 'yes, he has a huge short position on Tesla.' That didn’t work out too well.” See also: How To Buy Microsoft Stock Last year, Gates had said that electric trucks would never be a “practical solution” for carrying heavy loads over large distances. Musk was dismissive of Gates’ knowledge of electric vehicles and said “he has no clue.” On an earlier occasion, Musk had expressed displeasure over Gates’ purchase of a Porsche Taycan and described conversations with the former Microsoft executive as “underwhelming.” Price Action: Tesla shares closed nearly 2.4% lower at $796.22 on Tuesday and fell 0.6% in the after-hours session. On the same day, Microsoft shares closed nearly 0.5% lower at $243.70 and declined 0.18% in the after-hours session. Click here to check out Benzinga’s EV Hub for the latest electric vehicles news. Photo Courtesy: UK Department for International Development via Flickr See more from BenzingaClick here for options trades from BenzingaElon Musk's SpaceX Gets 60% Higher Valuation In Latest Funding Round At B: ReportWhy Apple Getting Increasingly Serious About Making Cars? 'Transportation' Dwarfs 'Smartphone' Market, Says Munster© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Today, we’re looking at two small-cap biotech firms whose stocks have struck a rut. Each company has hit a recent clinical setback that sent the share price falling, erasing previous gains and sending it back down to low levels. Setbacks of this sort are not uncommon in the biotech industry, and in fact highlight the risk and speculative nature of the industry. So what should investors do, when a stock collapses? Is this a matter of poor fundamentals? And has the stock’s price found its low point yet? That’s where the Wall Street pros come in. Noting that each is set to take back off on an upward trajectory, some 5-star analysts see an attractive entry point for both. Using TipRanks’ database, we found out that these two tickers have earned Moderate or Strong Buy consensus ratings from the analyst community, and boast strong upside potential. Cortexyme, Inc. (CRTX) The first beaten-down name we're looking at is Cortexyme, a clinical-stage biopharma company focused on degenerative diseases, especially Alzheimer’s. The company's lead candidate is COR388, also called atuzaginstat. Atuzaginstat is currently under investigation in the GAIN trial, a study of its efficacy against Alzheimer’s disease. The trial is fully enrolled, with 643 patients, and the company was moving toward an open label enrollment (OLE) section of the Phase 2/3 study. During a routine regulatory update, Cortexyme announced that the OLE phase would be halted, although the primary GAIN study will continue, with results due to be released in Q4 2021. The announcement of the partial halt triggered a 35% drop in share price. The partial hold was prompted by adverse events on the liver during the atuzaginstat trial. The hepatic symptoms were reversible and showed no long-term lasting effects. The FDA reviewed these records, and in collaboration with Cortexyme the decision was made to hold the OLE while continuing with GAIN. This decision allows the main thrust of the program to continue, while working out a new protocol for the OLE. The purpose of the OLE is to test long-term efficacy and tolerability of the drug. In a review of Cortexyme after the announcement, HC Wainwright’s 5-star analyst Andrew Fein noted, “Cortexyme's announcement of a partial clinical hold on the OLE study of atuzaginstat is disappointing, but the reversible nature of the liver toxicity might provide some ray of hope for Cortexyme. We believe that the pivotal trial's continuation suggests that the drug-induced liver injury might not be severe enough to halt the program.” Turning to the near-term, Fein adds, “Continuation of the GAIN trial is encouraging despite the partial hold on OLE. It suggests that FDA plans to wait for the additional data from the pivotal trial before coming to any conclusion. Management shared that nearly one-third of the GAIN patients have completed the study and way past the 12-week time point, suggesting that they are out of risk.” To this end, Fein rates CRTX a Buy, and his $76 price target indicates confidence in a 147% growth potential. (To watch Fein’s track record, click here) Overall, Cortexyme has a Moderate Buy rating from the analyst consensus, with 6 recent reviews breaking down 4 to 1 to 1, Buy-Hold-Sell. The stock’s $83.60 average price target suggests that Wall Street sees a high potential here, on the order of ~170% upside from the trading price of $30.74. (See CRTX stock analysis on TipRanks) Immunovant (IMVT) Next up is Immunovant, a clinical stage biopharmaceutical research firm, focused on developing treatments for patients with autoimmune disorders, a class of diseases in which the immune system attacks the patient’s own body. The firm’s lead drug candidate, IMVT-1401, is undergoing trials as a treatment for thyroid eye disease, myasthenia gravis, and warm autoimmune hemolytic anemia. The drug described as “a novel, fully human anti-FcRn monoclonal antibody,” delivered by subcutaneous injection. On February 2, Immunovant’s stock plunged 42%, and it has been falling ever since. The precipitating factor was an announcement by the company that IMVT-1401 has had its Phase 2b clinical trial, for thyroid eye disease, halted temporarily, due to patients experiencing dangerous rises in their LDL levels. LDLs are the potentially harmful form of cholesterol, which have been connected to cardiovascular disease. Despite the clinical setback, Stiffel’s 5-star analyst Derek Archila reiterated a Buy rating on IMVT shares, along with a $28 price target. This figure suggests a 52% upside potential from current levels. (To watch Archila’s track record, click here) “Interestingly, increases have only been seen in TED patients, and our review of the literature suggests a few things: (1) it's likely this is TED specific given the biology- see below for details, but we don't think similar LDL increases will be seen in other indications outside TED; and (2) other anti-thyroid therapies used in Graves/TED also see similar increases in LDL, which end up being transient. We think IMVT-1401, in away, is replicating this mechanism,” the analyst noted. Archila summed up, “While we will need to see additional data from the company to confirm… we don't think this program is dead.” Overall, the Strong Buy analyst consensus view on IMVT would suggest that Wall Street generally agrees with Archila’s assessment. This rating is derived from 8 recent reviews, which include 7 Buys and only a single Hold. The average price target here stands at $40.38, implying ~121% upside for the next 12 months. (See IMVT stock analysis on TipRanks) To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.
1h agoInvestor's Business Daily
Massive new fiscal spending under Democrats supports the gold bull case long term, but faster Fed tightening could weigh on gold for a while.
Comstock Mining Inc. is the stock du jour Wednesday, as it blasted higher more than fourfold on heavy volume to pace all premarket gainers. The mineral development and production company announced deals in which it secured rights for up to a 64% stake in Linico Corp., which is a lithium-ion battery (LIB) recycling company. Comstock will pay $4.5 million in cash and 3.0 million shares of its restricted common stock, which represents a total consideration of $10.75 billion. Comstock shares shot up 307.6%, and trading volume of 13.0 million shares was already above the full-day average over the past 30 days of 12.7 million shares. Linico recently acquired a battery metal recycling facility in Nevada from Aqua Metals Inc., and Aqua Metals is investing $2 million for a 10% stake in Linico. “We see spent lithium-ion batteries as a potent industrial mineral, and – as with any resource, we need the right team, technology, and infrastructure to extract and process it,” said Comstock Chief Executive Corrado De Gasperis. “This transaction assembles all three into an ecosystem of aligned partners, operating systemically on a common goal.” The latest available data showed that Comstock short interest was just 0.2% of the public float. The stock has rallied 120.6% over the past three months through Tuesday, while the S&P 500 has gained 9.0%.
His Berkshire Hathaway conglomerate recently started buying shares of Verizon and Chevron — both have attractive dividend yields well-supported by expected cash flow.
1h agoInvestor's Business Daily
Palantir stock fell as full-year 2021 revenue guidance came in slightly below expectations. Palantir stock also faces a test on Thursday when its IPO lock-up period expires.
(Bloomberg) — QuantumScape Corp., an electric-vehicle-battery startup, soared as much as 12% in late trading after saying it cleared a key hurdle in the development of its technology.The company, which is attempting to pioneer solid-state lithium-metal batteries for electric vehicles, said it was able to produce multilayer battery cells, a crucial stumbling block in taking the technology from the lab to the real world.“While there is still a lot of work to be done and we could encounter new challenges as we increase our layer count, this is an incredibly important result, and we are excited to have this so early in the year,” Chief Executive Officer Jagdeep Singh said in a letter to investors that was part of the company’s first quarterly financial report.The company is one of several startups and incumbents trying to develop solid-state batteries, an innovation that holds the promise of dramatically speeding up EV adoption by providing automakers with a safer, cheaper alternative to current lithium-ion batteries.To become commercially viable, the company needs to deal with three main issues. It must build bigger and multilayered batteries, compared with what it’s testing in a controlled laboratory setting. The current build has only four layers, and the company may need to have as many as a dozen in the commercial version.It also needs to develop a reliable manufacturing line for certain critical components, such as ceramic separators. Finally, it has to put all those pieces in a factory where it can spread billions of dollars in equipment and machinery costs over large production volumes.Shares of San Jose, California-based QuantumScape, which began trading Nov. 27 after it merged with the blank-check company, Kensington Capital Acquisition Corp., jumped as high as $56.70 in after-market trading Tuesday.Faster to MarketBeing able to build multilayer battery cells that essentially perform like single-layered cells may shave months off the time needed to bring QuantumScape’s batteries to consumer vehicles, Singh said in an interview.Crucially, it gives the company confidence to build a small pilot facility in San Jose that will produce engineering samples for automakers to put in “hundreds of test cars” as soon as 2023, the CEO said. QuantumScape intends to use those samples to woo customers beyond its largest shareholder, Volkswagen AG, Singh said on a call following the release of quarterly results.“Now we have the ability to make cells before the JV comes up with VW,” he said in an interview. “This is new, this wasn’t part of the plan before.”Volkswagen has committed to using QuantumScape’s battery technology in its EVs via a joint venture — if enough batteries can be produced and at competitive prices. QuantumScape estimates it will cost $1.6 billion to build that battery factory, a 50-50 venture with Volkswagen that’s supposed to start producing cells in 2024.The company closed the fourth quarter with more than $1 billion in cash and equivalents. Spending plans this year include capital outlays and operating costs of $230 million to $290 million, the company said. However with additional financing from Volkswagen and the assumed exercise of warrants, QuantumScape expects to head into 2022 with more than $900 million.(Updates with details of developments in seventh paragraph)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.
19h agoInvestor's Business Daily
Jeff Bezos is again the richest person in the world, reclaiming his title from Elon Musk, who has seen his wealth lag with the recent drop in Tesla stock.
1h agoYahoo Finance
Top news and what to watch in the markets on Wednesday, February 17, 2021.
The IRS issued more than 307 million direct payments worth a combined $412 billion during the first and second round of stimulus checks.
2h agoInvestor's Business Daily
The Dow Jones Industrial Average slid from record highs at the end of January, as the current stock market rally continues. The best Dow Jones stocks to buy and watch in February 2021 are Apple, Microsoft and Nike.
(Bloomberg) — On Jan. 28, the day after GameStop Corp. mania hit its crescendo on the back of a short squeeze for the record books, about $359 million worth of shares were caught in limbo.More than 1 million shares were deemed failed-to-deliver that day due either to buyers lacking cash to complete purchases or sellers not having the shares to settle trades, according to U.S. Securities and Exchange Commission data.The SEC report, which covers trading from Jan. 15 through the end of the month, is just one more indication of the dislocation in the market for the video game retailer’s shares.GameStop stock, for months among the most heavily shorted on the New York Stock Exchange, surged more than 1,700% from Jan. 1 through Jan. 27 as a legion of Reddit users piled on, forcing bearish traders to scramble for shares and brokers to take the highly unusual step of curbing trading.While the SEC’s list highlights the extent of the short squeeze, on Reddit’s WallStreetBets forum, where the GameStop trade was galvanized, it’s evidence of something else: the unproven theory that hedge funds were engaged in naked short-selling of the shares.Short sales — when an investor borrows shares, sells them and then tries to buy them back at a lower price to profit from the difference — are an everyday market occurrence. Naked short selling, the illegal practice of selling shares that aren’t known to exist, is just one possible cause of a failure-to-deliver, with more quotidian reasons being human error and administrative delays.“Fails-to-deliver can occur for a number of reasons on both long and short sales,” reads a disclaimer on the SEC website. “Therefore, fails-to-deliver are not necessarily the result of short selling, and are not evidence of abusive short selling or ‘naked’ short selling.”Failures to deliver can result in fines, losses as well as reputational harm, and in rare circumstances there’s also a risk they could lead to a reduction of market liquidity.One thing is clear: the Grapevine, Texas-based company is an anomaly in the data. Ranked by the dollar value of traded shares that couldn’t be delivered — a sum that was influenced by the ballooning price of GameStop’s shares — it was the only company to appear multiple times in the top 10 during the period. And it was only one of two companies, the other being Li Auto Inc., to feature atop a list dominated by exchange-traded funds.The data, which is released twice a month, tracks securities that had at least 10,000 shares that failed-to-deliver on a daily basis. The total number of shares for each day is a “cumulative number of all fails outstanding until that day, plus new fails that occur that day, less fails that settle that day,” according to the SEC’s website.About 2.1 million GameStop shares failed-to-deliver on Jan. 26 before falling to 138,179 on Jan. 29, the day after Robinhood and other brokerages began restricting trading in so-called meme stocks.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.
3h agoThe Wall Street Journal
Well-connected Chinese power players were behind layers of opaque investment vehicles that would have profited from the world’s largest stock listing. The information added to concerns about financial risk and anger at Ma’s outspoken criticism.
A number of factors are coming together in the market picture, and indicate a possible change in conditions in the mid-term. These include increases in commodity prices, specifically, oil prices, which have rallied recently. In addition, the January jobs numbers, released earlier this month, were disappointing at best – and grim, at worst. They, do, however, increase the chance that President Biden and the Democratic Congress will push a large-scale COVID relief package through to fruition. These factors are likely to pull in varying directions. The rise in oil prices suggests an upcoming squeeze in supply, while the possibility of further stimulus cash bodes well for fans of market liquidity. These developments, however, point toward a possible price reflationary climate. Against this backdrop, some investors are looking for ways to rebuild and defend their portfolios. And that will bring us to dividends. By providing a steady income stream, no matter what the market conditions, a reliable dividend stock provides a pad for your investment portfolio when the share stop appreciating. And so, we’ve opened up the TipRanks database and pulled the details on two stocks with high yields – at least 7%. Even better, these stocks are seen as Strong Buys by Wall Street’s analysts. Let’s find out why. Williams Companies (WMB) The first stock we'll look at is Williams Companies, a natural gas processing firm based in Oklahoma. Williams controls pipelines for natural gas, natural gas liquids, and oil gathering, in a network stretching from the Pacific Northwest, through the Rockies to the Gulf Coast, and across the South to the Mid-Atlantic. Williams’ core business is the processing and transport of natural gas, with crude oil and energy generation as secondary operations. The company’s footprint is huge – it handles almost one-third of all natural gas use in the US, both residential and commercial. Williams will report its 4Q20 results late this month – but a look at the Q3 results is informative. The company reported $1.93 billion at the top line, down 3.5% year-over-year but up 8.4% quarter-over-quarter, and the highest quarterly revenue so far released for 2020. Net earnings came in at 25 cents per share, flat from Q2 but up 38% year-over-year. The report was widely held as meeting or exceeding expectations, and the stock gained 7% in the two weeks after it was released. In a move that may indicate a solid Q4 earnings on the way, the company declared its next dividend, to be paid out on March 29. The 41-cent per common share payment is up 2.5% from the previous quarter, and annualizes to $1.64. At that rate, the dividend yields 7.1%. Williams has a 4-year history of dividend growth and maintenance, and typically raises the payment in the first quarter of the year. Covering the stock for RBC, 5-star analyst TJ Schultz wrote: “We believe Williams can hit the low-end of its 2020 EBITDA guidance. While we expect near-term growth in the NE to moderate, we think WMB should benefit from less than previously expected associated gas from the Permian. Given our long-term view, we estimate Williams can remain comfortably within investment grade credit metrics through our forecast period and keep the dividend intact.” To this end, Schultz rates WMB an Outperform (i.e. Buy), and his $26 price target suggests an upside of 13% in the next 12 months. (To watch Schultz’s track record, click here) With 8 recent reviews on record, including 7 Buys and just 1 Hold, WMB has earned its Strong Buy analyst consensus rating. While the stock has gained in recent months, reaching $23, the average price target of $25.71 implies it still has room for ~12% growth this year. (See WMB stock analysis on TipRanks) AGNC Investment (AGNC) Next up is AGNC Investment, a real estate investment trust. It’s no surprise to find a REIT as a dividend champ – these companies are required by tax codes to return a high percentage of profits directly to shareholders, and frequently use dividends as the vehicle for compliance. AGNC, based in Maryland, focuses on MBSs (mortgage-backed securities) with backing and guarantees from the US government. These securities make up some two-thirds of the company’s total portfolio, or $65.1 billion out of the $97.9 billion total. AGNC’s most recent quarterly returns, for 4Q20, showed $459 million in net revenue, and a net income per share of $1.37. While down yoy, the EPS was the strongest recorded for 2020. For the full year, AGNC reported $1.68 billion in total revenues, and $1.56 per share paid out in dividends. The current dividend, 12 cents per common share paid out monthly, will annualize to $1.44; the difference from last year’s higher annualization rate is due to a dividend cut implemented in April in response to the coronavirus crisis. At the current rate, the dividend gives investors a robust yield of 8.8%, and is easily affordable for the company given current income. Among AGNC's bulls is Maxim analyst Michael Diana who wrote: “AGNC has retained a competitive yield on book value relative to other mortgage REITs (mREITS), even as it has out-earned its dividend and repurchased shares. While turmoil in the mortgage markets at the end of March resulted in losses and lower book values for all mortgage REITs, AGNC was able to meet all of its margin calls and, importantly, take relatively fewer realized losses and therefore retain more earnings power post-turmoil.” Based on all of the above, Diana rates AGNC a Buy, along with an $18 price target. This figure implies a ~10% upside potential from current levels. (To watch Diana’s track record, click here) Wall Street is on the same page. Over the last couple of months, AGNC has received 7 Buys and a single Hold — all add up to a Strong Buy consensus rating. However, the $16.69 average price target suggests shares will remain range bound for the foreseeable future. (See AGNC stock analysis on TipRanks) To find good ideas for dividend stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.
Berkshire Hathaway Inc (NYSE: BRK-A) (NYSE: BRK-B) cut its positions in Apple Inc (NASDAQ: AAPL) and piled on stocks of drug, telecom, and oil companies in the latest quarter, according to filings made with the U.S. Securities and Exchange Commission. What Happened: The Warren Buffett-led company shed its Apple stake by 6% to 887 million shares in the quarter, but at the same time has upped its investments in AbbVie Inc (NYSE: ABBV) by 20%, Bristol-Myers Squibb Company (NYSE: BMY) by 11%, and Merck & Co, Inc (NYSE: MRK) by 28%. The conglomerate increased its exposure to T-Mobile US, Inc (NASDAQ: TMUS) by 1.36% to 5.2 million shares and also added 146.7 million shares of Verizon Communications Inc (NYSE: VZ). See Also: Warren Buffett's Berkshire Bets On These Four Drugmakers Amid Pandemic Berkshire picked up a fresh stake of 48.5 million Chevron Corporation (NYSE: CVX) shares and increased its investment in The Kroger Co (NYSE: KR) by 34%. Other changes include a 59% cut in exposure to Wells Fargo & Co (NYSE: WFC) and a 28% cut in Suncor Energy Inc (NYSE: SU) stake. Why It Matters: Apple is still the largest single investment in Berkshire’s portfolio, as of the latest 13F filing, and the investment is worth about $120 billion. See Also: Warren Buffett Called Bitcoin 'Rat Poison' — Now It's Closing In On Berkshire Hathaway's Valuation Apple shares closed nearly 1.6% lower at $133.19 on Tuesday and fell another 0.41% in the after-hours session. In the after-hours trading on Tuesday — AbbVie shares were up 0.42% at $104.64. Bristol-Myers shares rose 0.34% to $59.60. T-Mobile shares rose 0.86% to $123.05. Verizon shares shot up 3.05% to $55.80 in the after-hours trading, while Chevron shares rose 2.54% to $95.50. Wells Fargo shares were down 0.11% in the after-hours. Kroger and Suncor shares remained largely unchanged. Price Action: Berkshire Hathaway Class A shares closed 1.23% higher at $369,333. The company’s class B shares closed 1.15% higher at $245.28 and fell 0.11% in the after-hours session. Photo by Fortune Live Media on Flickr See more from BenzingaClick here for options trades from BenzingaTikTok In Negotiations To Go Public On NYSE: Chinese MediaWhy Apple Getting Increasingly Serious About Making Cars? 'Transportation' Dwarfs 'Smartphone' Market, Says Munster© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
14h agoMore Stories
Join mobilsocial social network mobilsocial